Keros Therapeutics Inc expected to post a loss of $1.35 a share - Earnings Preview

Keros Therapeutics

30/10/2023 18:33

* Keros Therapeutics Inc  KROS.OQ   KROS.O  is expected
to show no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Keros Therapeutics
Inc is
for a loss of $1.35 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Keros
Therapeutics Inc is $86​, above​ its last closing price
of $27.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.33       -1.34      -1.27     Beat    5.1
 Mar. 31 2023  -1.13       -1.12      -1.26     Missed  -12.2
 Dec. 31 2022  -1.08       -1.10      -1.09     Beat    0.7​
 Sep. 30 2022  -1.23       -1.23      -0.92     Beat    25.3
 ​​Jun.        -1.05       -1.06      -1.13     Missed  -6.8
 30 2022                                                
 Mar. 31 2022  -0.86       -0.86      -1.01     Missed  -17.1​
 Dec. 31 2021  -0.97       -0.92      -0.30     Beat    67.3
 Sep. 30 2021  -0.72       -0.72      -0.87     Missed  -20.4
 This summary was machine generated October 30 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated